<DOC>
	<DOCNO>NCT00659984</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , iodine I 131 metaiodobenzylguanidine ( MIBG ) , may carry radiation directly tumor cell harm normal cell . A bone marrow peripheral stem cell transplant use stem cell patient may able replace blood-forming cell destroy I 131 MIBG . PURPOSE : This phase II trial study side effect best dose iodine I 131 MIBG follow stem cell transplant treat young patient relapsed refractory high-risk neuroblastoma .</brief_summary>
	<brief_title>N2007-01 : Ultratrace™ Iobenguane I 131 Patients With Relapsed/Refractory High-Risk Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) patient relapsed/refractory high-risk neuroblastoma . Secondary - To describe toxicity follow treatment ^131I-MIBG patient relapsed/refractory high-risk neuroblastoma . - To estimate radiation absorb dose measurable lesion standard set normal organ follow 0.1 mCi/kg [ 3.7 MBq/kg ] ( minimum dose 1.0 mCi [ 37 MBq ] exceed 5.0 mCi [ 185 MBq ] ) intravenous administration ^131I-MIBG patient relapsed/refractory high-risk neuroblastoma . - To describe , within confines phase IIa trial , objective tumor response follow treatment ^131I-MIBG patient relapsed/refractory high-risk neuroblastoma . - To explore dose-response follow treatment ^131I-MIBG patient relapsed/refractory high-risk neuroblastoma . - To explore quality life assessment follow treatment ^131I-MIBG patient relapsed/refractory high-risk neuroblastoma . OUTLINE : - Dosimetry : Patients receive dosimetric dose iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) IV 1-3 minute . Patients undergo 2 3 MIBG scan within 5 day dosimetry dose assess biodistribution tumor uptake . Patients normal tumor uptake biodistribution proceed treatment . - Treatment : Within 1-4 week dosimetric dose , patient normal tumor uptake biodistribution receive therapeutic dose ^131I-MIBG IV 1 hour day 0 undergo MIBG scan day 7 . Patients proceed autologous stem cell infusion . - Autologous stem cell infusion : Patients receive infusion autologous stem cell peripheral blood bone marrow day 14 . Patients ANC &lt; 500/µl point autologous stem cell infusion receive filgrastim ( G-CSF ) IV subcutaneously daily ANC &gt; 2,000/µl . Patients complete quality life questionnaire baseline day 60 . After completion study treatment , patient follow day 60 periodically thereafter .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Patients must least one year 30 year age register study . Patients must high risk neuroblastoma either tumor leave treatment start diagnosis tumor grow back ( relapse ) get treatment Patients must MIBG scan do must positive neuroblastoma . Patients must PBSC bone marrow stem cell product available meet study criterion . If n't already stem cell frozen away must able stem cell pheresis do collect necessary amount stem cell study entry stem cell must meet study criterion . Patients must adequate heart , lung , liver , kidney bone marrow function . They stem cell transplant use another person stem cell donor . ( You still study previous transplant use stem cell ) They medical problem could get much bad treatment . They dialysis badly work kidney kidney problem . They pregnant breast feed . They tumor brain spinal cord see CT MRI scan one month start treatment They total body radiation radiation entire belly . They know allergy MIBG , iodine SSKI . They ca n't cooperate special precaution need UltratraceTM MIBG treatment safety monitoring requirement study..</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>